The epidermal growth factor receptor (EGFR; ErbB-1; HER1 in humans) is a transmembrane protein that is a receptor for members of the epidermal growth factor family (EGF family) of extracellular protein ligands.

The epidermal growth factor receptor is a member of the ErbB family of receptors, a subfamily of four closely related receptor tyrosine kinases: EGFR (ErbB-1), HER2/neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). In many cancer types, mutations affecting EGFR expression or activity could result in cancer

EGFR (Epidermal Growth Factor Receptor) is a cell surface receptor that plays a crucial role in the regulation of cell growth, survival, differentiation, and proliferation. It is part of the receptor tyrosine kinase (RTK) family, which are proteins that transmit signals from the outside of the cell to the inside, triggering various cellular processes.

Key Points:

Gene Function:

• EGFR is encoded by the EGFR gene and belongs to a family of receptors that are activated by specific growth factors, such as epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α).
• Upon binding of these growth factors, EGFR undergoes dimerization (pairing with another EGFR molecule) and autophosphorylation (adding phosphate groups to itself), which activates a downstream signaling cascade. This cascade leads to the activation of several intracellular pathways that regulate processes such as:
  • Cell division: Stimulating cells to divide and grow.
  • Cell survival: Protecting cells from apoptosis (programmed cell death).
  • Cell migration: Important for processes like wound healing and cancer metastasis.
• Mutations and Aberrations in EGFR:
  • Mutations in EGFR are commonly found in various types of cancers, particularly non-small cell lung cancer (NSCLC). These mutations can lead to constant activation of the receptor, even in the absence of its normal ligands, resulting in uncontrolled cell growth and tumor formation.
  • The most well-known mutation in EGFR is the exon 19 deletion and the L858R point mutation in exon 21. These mutations lead to constitutive activation of the EGFR signaling pathway.

Cancer Types Associated with EGFR Mutations:

• Non-small cell lung cancer (NSCLC): Mutations in EGFR are common in NSCLC, particularly in adenocarcinomas. These mutations are especially prevalent in non-smokers, younger patients, and those of Asian descent.
• Head and neck squamous cell carcinoma (HNSCC): EGFR overexpression or mutation is also frequently observed in head and neck cancers.
• Colorectal cancer: EGFR is often overexpressed, though mutations are less common compared to lung cancer.
• Other cancers: EGFR mutations or overexpression can also be found in breast cancer, gliomas, and bladder cancer.

Therapeutic Relevance:

• EGFR inhibitors are used as targeted therapies for cancers with EGFR mutations or overexpression. These therapies block the activation of EGFR, preventing the downstream signaling that leads to tumor growth and survival.
• Tyrosine kinase inhibitors (TKIs): These drugs block the intracellular kinase activity of EGFR, preventing signal transmission.
• Gefitinib (Iressa), Erlotinib (Tarceva), and Afatinib (Gilotrif) are examples of EGFR TKIs that target EGFR mutations in NSCLC and other cancers.
• Monoclonal antibodies: Drugs like Cetuximab (Erbitux) and Panitumumab (Vectibix) are monoclonal antibodies that bind to the extracellular domain of EGFR, preventing its activation.
• Resistance to EGFR inhibitors: Over time, cancers may develop resistance to EGFR-targeted therapies. A common resistance mutation is the T790M mutation in exon 20 of EGFR, which reduces the effectiveness of first- and second-generation EGFR inhibitors. Newer drugs like Osimertinib (Tagrisso) have been developed to target this resistant mutation.

Mechanism of Action in Cancer:

• In cancer cells, the activation of EGFR signaling pathways leads to enhanced cell survival, proliferation, and invasion. EGFR mutations or overexpression drive tumorigenesis and can promote metastasis (the spread of cancer to other organs).
• By inhibiting EGFR, targeted therapies aim to block these processes and slow down or stop tumor growth.

Resistance Mechanisms:

• Secondary mutations: In addition to the T790M mutation, other resistance mechanisms include amplification of the EGFR gene or activation of alternate signaling pathways (e.g., MET amplification).
• Overcoming resistance: Newer drugs, such as Osimertinib (for T790M mutations), and combination therapies (e.g., EGFR inhibitors with chemotherapy or immunotherapy) are being explored to overcome resistance.

Summary of EGFR in Cancer:

• EGFR is a cell surface receptor involved in regulating cell growth and survival.
• Mutations or overexpression of EGFR can lead to uncontrolled cell division and tumor growth, particularly in cancers like non-small cell lung cancer, head and neck cancer, and colorectal cancer.
• EGFR-targeted therapies such as TKIs and monoclonal antibodies are used to block the signaling pathway and treat EGFR-driven cancers.
• Resistance to EGFR inhibitors remains a challenge, but newer therapies and combination approaches are being developed to address this issue.

EGFR plays a crucial role in cancer biology, making it a significant target for personalized cancer treatments.